With that, I will turn the call over to Glaukos Corporation’s Chairman and CEO, Thomas William Burns. Today, Glaukos Corporation reported record fourth quarter consolidated net sales of $143.1 million ...
As I look back on the past year, it is clear that 2025 was one of the most significant and value-creating years in Halozyme Therapeutics, Inc.'s history. This level of execution has created a clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results